• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌症中双向基因的协同调控与功能。

Co-regulation and function of / bidirectional genes in cancer.

机构信息

Eppley Institute for Cancer Research and Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, United States.

Departments of Gynecologic Oncology, Immunology, and Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, United States.

出版信息

Elife. 2021 Apr 23;10:e55070. doi: 10.7554/eLife.55070.

DOI:10.7554/eLife.55070
PMID:33890574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8104967/
Abstract

The FOXM1 transcription factor is an oncoprotein and a top biomarker of poor prognosis in human cancer. Overexpression and activation of FOXM1 is frequent in high-grade serous carcinoma (HGSC), the most common and lethal form of human ovarian cancer, and is linked to copy number gains at chromosome 12p13.33. We show that is co-amplified and co-expressed with , a gene involved in the ATR-Chk1 signaling pathway that functions in the DNA replication stress response. We demonstrate that and are head-to-head (i.e., bidirectional) genes (BDG) regulated by a bidirectional promoter (BDP) (named F/R-BDP). FOXM1 and RHNO1 each promote oncogenic phenotypes in HGSC cells, including clonogenic growth, DNA homologous recombination repair, and poly-ADP ribosylase inhibitor resistance. FOXM1 and RHNO1 are one of the first examples of oncogenic BDG, and therapeutic targeting of FOXM1/RHNO1 BDG is a potential therapeutic approach for ovarian and other cancers.

摘要

叉头框蛋白 M1（FOXM1）转录因子是一种癌蛋白，也是人类癌症中预后不良的重要生物标志物。FOXM1 的过表达和激活在高级别浆液性卵巢癌（HGSC）中很常见，HGSC 是最常见且致命的卵巢癌形式，与染色体 12p13.33 的拷贝数增加有关。我们发现，在参与 ATR-Chk1 信号通路的基因 和 中，FOXM1 与 共扩增和共表达，该基因在 DNA 复制应激反应中发挥作用。我们证明 和 是由双向启动子（BDP）（命名为 F/R-BDP）调控的头对头（即双向）基因（BDG）。FOXM1 和 RHNO1 均可促进 HGSC 细胞的致癌表型，包括集落形成、DNA 同源重组修复和多聚 ADP 核糖酶抑制剂耐药性。FOXM1 和 RHNO1 是第一个致癌 BDG 例子之一，靶向 FOXM1/RHNO1 BDG 的治疗可能是卵巢癌和其他癌症的潜在治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/5ac1eb6145c7/elife-55070-fig21.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/c3b27d755f37/elife-55070-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/f2207397c2e6/elife-55070-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/8f59df73cf81/elife-55070-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/113d7ce71d8a/elife-55070-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/e6a05bf8a993/elife-55070-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/31a66841b593/elife-55070-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/79962ff9e4ff/elife-55070-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/1024163c257b/elife-55070-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/4349d1d80a20/elife-55070-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/d2a6b96f0120/elife-55070-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/034144340a27/elife-55070-fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/729b121cc936/elife-55070-fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/54fa8bc6d76a/elife-55070-fig9-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/2bec42610e79/elife-55070-fig9-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/46594d190202/elife-55070-fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/58e3b9727e68/elife-55070-fig11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/dc9d635b249f/elife-55070-fig11-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/0d387f31593b/elife-55070-fig11-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/5d8b1d603db4/elife-55070-fig12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/e234778fce67/elife-55070-fig12-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/dd8eb119d03c/elife-55070-fig13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/117c1d245f21/elife-55070-fig14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/fd361a4446cd/elife-55070-fig15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/85f116e9474f/elife-55070-fig16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/1fe53125aa75/elife-55070-fig17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/c56545bdda34/elife-55070-fig17-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/a3aad24f11bb/elife-55070-fig18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/a056fa5978cd/elife-55070-fig19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/fe1fc817fa3e/elife-55070-fig20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/5ac1eb6145c7/elife-55070-fig21.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/c3b27d755f37/elife-55070-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/f2207397c2e6/elife-55070-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/8f59df73cf81/elife-55070-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/113d7ce71d8a/elife-55070-fig2-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/e6a05bf8a993/elife-55070-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/31a66841b593/elife-55070-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/79962ff9e4ff/elife-55070-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/1024163c257b/elife-55070-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/4349d1d80a20/elife-55070-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/d2a6b96f0120/elife-55070-fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/034144340a27/elife-55070-fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/729b121cc936/elife-55070-fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/54fa8bc6d76a/elife-55070-fig9-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/2bec42610e79/elife-55070-fig9-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/46594d190202/elife-55070-fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/58e3b9727e68/elife-55070-fig11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/dc9d635b249f/elife-55070-fig11-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/0d387f31593b/elife-55070-fig11-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/5d8b1d603db4/elife-55070-fig12.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/e234778fce67/elife-55070-fig12-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/dd8eb119d03c/elife-55070-fig13.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/117c1d245f21/elife-55070-fig14.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/fd361a4446cd/elife-55070-fig15.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/85f116e9474f/elife-55070-fig16.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/1fe53125aa75/elife-55070-fig17.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/c56545bdda34/elife-55070-fig17-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/a3aad24f11bb/elife-55070-fig18.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/a056fa5978cd/elife-55070-fig19.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/fe1fc817fa3e/elife-55070-fig20.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/32c2/8104967/5ac1eb6145c7/elife-55070-fig21.jpg

相似文献

1
Co-regulation and function of / bidirectional genes in cancer.癌症中双向基因的协同调控与功能。
Elife. 2021 Apr 23;10:e55070. doi: 10.7554/eLife.55070.
2
Loss of PAX8 in high-grade serous ovarian cancer reduces cell survival despite unique modes of action in the fallopian tube and ovarian surface epithelium.在高级别浆液性卵巢癌中，PAX8缺失会降低细胞存活率，尽管其在输卵管和卵巢表面上皮细胞中有独特的作用方式。
Oncotarget. 2016 May 31;7(22):32785-95. doi: 10.18632/oncotarget.9051.
3
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.PARP 抑制剂增加了对 ATR/CHK1 检查点信号的依赖，从而导致合成致死——一种独立于 HR 有效性的上皮性卵巢癌细胞的替代治疗策略。
Int J Mol Sci. 2020 Dec 19;21(24):9715. doi: 10.3390/ijms21249715.
4
FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.在非浆液性上皮性卵巢癌患者中，FOXM1表达与化疗耐药及不良预后显著相关。
J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.
5
RHNO1: at the crossroads of DNA replication stress, DNA repair, and cancer.RHNO1：位于 DNA 复制应激、DNA 修复和癌症的十字路口。
Oncogene. 2024 Aug;43(35):2613-2620. doi: 10.1038/s41388-024-03117-x. Epub 2024 Aug 6.
6
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.通过细胞周期检验点抑制，可以克服 PARP 抑制剂耐药的复制叉稳定恢复机制。
Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11.
7
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.ATR/CHK1 通路在高级别卵巢癌复制应激靶向治疗中的作用。
J Hematol Oncol. 2020 Apr 21;13(1):39. doi: 10.1186/s13045-020-00874-6.
8
FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer.在高级别浆液性卵巢癌中，FOXM1是溶血磷脂酸（LPA）和Yes相关蛋白（YAP）致癌信号通路的下游靶点。
Oncotarget. 2015 Sep 29;6(29):27688-99. doi: 10.18632/oncotarget.4280.
9
Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors.揭示与奥拉帕利耐药和卵巢癌细胞 PEO1-OR 再敏化相关的 miRNA-mRNA 调控网络，该通路抑制剂为 ATR/CHK1 通路抑制剂。
Cells. 2024 May 17;13(10):867. doi: 10.3390/cells13100867.
10
VprBP/DCAF1 Regulates the Degradation and Nonproteolytic Activation of the Cell Cycle Transcription Factor FoxM1.VprBP/DCAF1调控细胞周期转录因子FoxM1的降解及非蛋白酶解激活。
Mol Cell Biol. 2017 Jun 15;37(13). doi: 10.1128/MCB.00609-16. Print 2017 Jul 1.

引用本文的文献

1
Progress of targeted FOX family therapy in ovarian cancer.卵巢癌中靶向FOX家族治疗的进展
Front Pharmacol. 2025 Jul 17;16:1604998. doi: 10.3389/fphar.2025.1604998. eCollection 2025.
2
FOXM1 expression reverts aging chromatin profiles through repression of the senescence-associated pioneer factor AP-1.FOXM1表达通过抑制衰老相关的先锋因子AP-1来逆转衰老染色质图谱。
Nat Commun. 2025 Mar 25;16(1):2931. doi: 10.1038/s41467-025-57503-4.
3
RHNO1: at the crossroads of DNA replication stress, DNA repair, and cancer.RHNO1：位于 DNA 复制应激、DNA 修复和癌症的十字路口。

本文引用的文献

1
FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis.叉头框蛋白M1（FOXM1）与癌症：细胞信号传导异常破坏体内平衡。
Front Oncol. 2021 Feb 15;10:626836. doi: 10.3389/fonc.2020.626836. eCollection 2020.
2
FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo.卵巢癌组织培养中FOXM1的抑制影响体外个体治疗敏感性。
Cancers (Basel). 2021 Feb 25;13(5):956. doi: 10.3390/cancers13050956.
3
MMB-FOXM1-driven premature mitosis is required for CHK1 inhibitor sensitivity.MMB-FOXM1 驱动的过早有丝分裂是 CHK1 抑制剂敏感性所必需的。
Oncogene. 2024 Aug;43(35):2613-2620. doi: 10.1038/s41388-024-03117-x. Epub 2024 Aug 6.
4
Molecular models of bidirectional promoter regulation.双向启动子调控的分子模型。
Curr Opin Struct Biol. 2024 Aug;87:102865. doi: 10.1016/j.sbi.2024.102865. Epub 2024 Jun 20.
5
PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives.PROTACs 在卵巢癌中的应用：现状与展望。
Int J Mol Sci. 2024 May 7;25(10):5067. doi: 10.3390/ijms25105067.
6
TrxT and dhd are dispensable for Drosophila brain development but essential for l(3)mbt brain tumour growth.TrxT 和 dhd 在果蝇大脑发育中是可有可无的，但对于 l(3)mbt 脑肿瘤的生长却是必不可少的。
EMBO Rep. 2024 Jul;25(7):2842-2860. doi: 10.1038/s44319-024-00154-1. Epub 2024 May 15.
7
NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells.NB 化合物是高效的 FOXM1 抑制剂，可用于治疗高级别浆液性卵巢癌细胞。
J Ovarian Res. 2024 May 4;17(1):94. doi: 10.1186/s13048-024-01421-4.
8
Abundant binary promoter switches in lineage-determining transcription factors indicate a digital component of cell fate determination.谱系确定转录因子中丰富的二元启动子开关表明细胞命运决定的数字成分。
Cell Rep. 2023 Nov 28;42(11):113454. doi: 10.1016/j.celrep.2023.113454. Epub 2023 Nov 16.
9
The DNA-binding induced (de)AMPylation activity of a Coxiella burnetii Fic enzyme targets Histone H3.贝氏考克斯体 Fic 酶的 DNA 结合诱导（去）腺苷酸化活性靶向组蛋白 H3。
Commun Biol. 2023 Nov 6;6(1):1124. doi: 10.1038/s42003-023-05494-7.
10
FOXM1 is critical for the fitness recovery of chromosomally unstable cells.FOXM1 对于染色体不稳定细胞的适应性恢复至关重要。
Cell Death Dis. 2023 Jul 14;14(7):430. doi: 10.1038/s41419-023-05946-2.
Cell Rep. 2021 Mar 2;34(9):108808. doi: 10.1016/j.celrep.2021.108808.
4
Identification of a Five-Gene Prognostic Model and Its Potential Drug Repurposing in Colorectal Cancer Based on TCGA, GTEx and GEO Databases.基于TCGA、GTEx和GEO数据库的结直肠癌五基因预后模型的鉴定及其潜在的药物再利用
Front Genet. 2021 Jan 18;11:622659. doi: 10.3389/fgene.2020.622659. eCollection 2020.
5
Pan-Cancer Analysis of Head-to-Head Gene Pairs in Terms of Transcriptional Activity, Co-expression and Regulation.基于转录活性、共表达和调控的头对头基因对的泛癌分析
Front Genet. 2021 Jan 7;11:560997. doi: 10.3389/fgene.2020.560997. eCollection 2020.
6
HEDGEHOG/GLI Modulates the PRR11-SKA2 Bidirectional Transcription Unit in Lung Squamous Cell Carcinomas.刺猬/GLI 调节肺鳞癌中 PRR11-SKA2 双向转录单元。
Genes (Basel). 2021 Jan 19;12(1):120. doi: 10.3390/genes12010120.
7
Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.循环肿瘤 DNA 全基因组拷贝数改变作为高级别浆液性卵巢癌患者的新型生物标志物。
Clin Cancer Res. 2021 May 1;27(9):2549-2559. doi: 10.1158/1078-0432.CCR-20-3345. Epub 2020 Dec 15.
8
Replication stress and FOXM1 drive radiation induced genomic instability and cell transformation.复制压力和 FOXM1 驱动辐射诱导的基因组不稳定性和细胞转化。
PLoS One. 2020 Nov 30;15(11):e0235998. doi: 10.1371/journal.pone.0235998. eCollection 2020.
9
FOXM1 drives HPV+ HNSCC sensitivity to WEE1 inhibition.FOXM1 驱动 HPV+ HNSCC 对 WEE1 抑制的敏感性。
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28287-28296. doi: 10.1073/pnas.2013921117. Epub 2020 Oct 22.
10
Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling.卵巢癌腹膜转移蕴藏受 FOXM1 和 EGFR/ERBB2 信号调控的治疗弱点。
Cancer Res. 2020 Dec 15;80(24):5554-5568. doi: 10.1158/0008-5472.CAN-19-3717. Epub 2020 Oct 21.